000121032 001__ 121032
000121032 005__ 20240319081004.0
000121032 0247_ $$2doi$$a10.3389/fmed.2021.808608
000121032 0248_ $$2sideral$$a130386
000121032 037__ $$aART-2022-130386
000121032 041__ $$aeng
000121032 100__ $$aGracia, Borja Del Carmelo
000121032 245__ $$aCOVID GEAS: COVID-19 National Survey in Patients With Systemic Autoimmune Diseases
000121032 260__ $$c2022
000121032 5060_ $$aAccess copy available to the general public$$fUnrestricted
000121032 5203_ $$aObjectives COVID-19 outcomes in population with systemic autoimmune diseases (SAD) remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 infection in people with rheumatic disease.MethodsTwo phases cross-sectional survey of individuals with rheumatic disease in April 2020 and October 2020. COVID infection, severity of disease, age, sex, smoking status, underlying rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analyzed.ResultsA total of 1,529 individuals with autoimmunity disease diagnosis were included. Out of 50 positive patients, 21 required telephone medical assistance, 16 received assessment by primary care physician, 9 were evaluated in Emergency Department and 4 patient required hospitalization. Multivariate analysis was performed without obtaining differences in any of the systemic autoimmune diseases. Regarding the treatments, significant differences were found (p 0.011) in the treatment with anti-TNF-alpha agents with OR 3.422 (1.322–8.858) and a trend to significance (p 0.094) was observed in patients receiving mycophenolate treatment [OR 2.016 (0.996–4-081)].ConclusionsAnti-TNF-alpha treatment was associated with more than 3-fold risk of suffering from SARS-CoV-2 infection, although in all cases infection was mild. Cumulative incidence in patients with SAD was up to 5 times higher than general population but with great differences between autoimmune diseases.
000121032 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000121032 590__ $$a3.9$$b2022
000121032 592__ $$a0.926$$b2022
000121032 591__ $$aMEDICINE, GENERAL & INTERNAL$$b58 / 169 = 0.343$$c2022$$dQ2$$eT2
000121032 593__ $$aMedicine (miscellaneous)$$c2022$$dQ1
000121032 594__ $$a3.6$$b2022
000121032 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000121032 700__ $$0(orcid)0000-0002-9868-6498$$aSáez, Luis$$uUniversidad de Zaragoza
000121032 700__ $$aPallarés, Lucio
000121032 700__ $$aVelilla, Jose
000121032 700__ $$0(orcid)0000-0002-7815-8356$$aMarín, Adela$$uUniversidad de Zaragoza
000121032 700__ $$aMartinez-Lostao, Luis
000121032 700__ $$aSimeón, Carmen Pilar
000121032 700__ $$aFanlo, Patricia
000121032 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000121032 773__ $$g8 (2022), [10 PP.]$$pFront. med.$$tFrontiers in Medicine$$x2296-858X
000121032 8564_ $$s611308$$uhttps://zaguan.unizar.es/record/121032/files/texto_completo.pdf$$yVersión publicada
000121032 8564_ $$s2273199$$uhttps://zaguan.unizar.es/record/121032/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000121032 909CO $$ooai:zaguan.unizar.es:121032$$particulos$$pdriver
000121032 951__ $$a2024-03-18-14:28:26
000121032 980__ $$aARTICLE